Patents by Inventor Barbara Foster

Barbara Foster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10487362
    Abstract: Provided are compositions and methods for detecting in a sample the presence or absence, and/or the amount, of a small nucleolar RNA (snoRNA) HBII-52, also known as SNORD115. The compositions and methods are useful in diagnosis, prognosis, therapy recommendations, therapy, and monitoring of therapy for individuals who have a disorder that is positively correlated with elevated HBII-52, such as cancer, and particularly for prostate cancer. Kits containing primers for detecting and/or amplifying HBII-52 from a biological sample are provided. The disclosure includes a method for monitoring an individual undergoing therapy for a disorder associated with HBII-52 expression, a method for identifying an individual as a candidate for therapy with an antagonist of 5-HT2cR, and a method for therapy by administering to a subject a therapeutically effective amount of an antagonist of 5-HT2cR.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: November 26, 2019
    Assignee: Health Research, Inc.
    Inventors: Barbara Foster, Steven J. Seedhouse, Jason Kirk
  • Publication number: 20150354011
    Abstract: Provided are compositions and methods for detecting in a sample the presence or absence, and/or the amount, of a small nucleolar RNA (snoRNA) HBII-52, also known as SNORD115. The compositions and methods are useful in diagnosis, prognosis, therapy recommendations, therapy, and monitoring of therapy for individuals who have a disorder that is positively correlated with elevated HBII-52, such as cancer, and particularly for prostate cancer. Kits containing primers for detecting and/or amplifying HBII-52 from a biological sample are provided. The disclosure includes a method for monitoring an individual undergoing therapy for a disorder associated with HBII-52 expression, a method for identifying an individual as a candidate for therapy with an antagonist of 5-HT2cR, and a method for therapy by administering to a subject a therapeutically effective amount of an antagonist of 5-HT2cR.
    Type: Application
    Filed: January 9, 2014
    Publication date: December 10, 2015
    Inventors: Barbara FOSTER, Steven J. SEEDHOUSE
  • Publication number: 20100019640
    Abstract: Disclosed is a portable apparatus for cooling and carrying articles. The portable apparatus comprises a first enclosure, a second enclosure, a refrigeration system and a power source. The first enclosure includes a first inner space and the second enclosure includes a second inner space. The second enclosure is detachably attached to the first enclosure to configure a closed inner space by joining the first inner space and the second inner space. The closed inner space is capable of accommodating the articles therein. Further, the refrigeration system is disposed within at least one of the first enclosure and the second enclosure for cooling the closed inner space. Furthermore, the power source is detachably attached to at least one of the first enclosure and the second enclosure. The power source is capable of supplying power to the refrigeration system for cooling the closed inner space, thereby cooling the articles accommodated therein.
    Type: Application
    Filed: July 22, 2008
    Publication date: January 28, 2010
    Inventor: Barbara Foster
  • Patent number: 7087613
    Abstract: A method of monotherapy for a subject suffering from abnormal cell growth expressing the epidermal growth factor receptor (EGFR) which comprises orally administering to the subject a therapeutically effective amount of a crystalline polymorph of the hydrochloride salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine so as to treat the subject.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: August 8, 2006
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Timothy Norris, Jeffrey W. Raggon, Richard D. Connell, James D. Moyer, Michael J. Morin, Shama M. Kajiji, Barbara A. Foster, Karen J. Ferrante, Sandra L. Silberman
  • Patent number: 6900221
    Abstract: The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride, as well other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound.
    Type: Grant
    Filed: November 9, 2000
    Date of Patent: May 31, 2005
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Timothy Norris, Jeffrey W. Raggon, Richard D. Connell, James D. Moyer, Michael J. Morin, Shama M. Kajiji, Barbara A. Foster, Karen J. Ferrante, Sandra L. Silberman
  • Publication number: 20050090500
    Abstract: The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride, as well other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound.
    Type: Application
    Filed: November 18, 2004
    Publication date: April 28, 2005
    Inventors: Timothy Norris, Jeffrey Raggon, Richard Connell, James Moyer, Michael Morin, Shama Kajiji, Barbara Foster, Karen Ferrante, Sandra Silberman
  • Publication number: 20030166016
    Abstract: Disclosed herein are novel methods for measuring the activity of one or more cyclin dependent kinases (CDKs) in a sample, based upon the quantitation of CDK-phosphorylated Rb protein. The method for measuring cyclin-dependent kinase (CDK) activity includes the following: i) contacting the sample with an anti-retinoblastoma protein (Rb) capture antibody that specifically recognizes a CDK-phosphorylated Rb and isolating the capture antibody-Rb complex; ii) contacting the capture antibody-Rb complex with an anti-Rb primary antibody and isolating the capture antibody-Rb-primary antibody complex; and iii) measuring the amount of CDK-phosphorylated Rb in the sample by quantitating the primary antibody present in the capture antibody-Rb-primary antibody complex. These methods may be used to assess intracellular CDK activity in cultured cells or in cells taken from an animal. Also disclosed are methods of identifying an agent that modulates the CDK activity.
    Type: Application
    Filed: April 25, 2001
    Publication date: September 4, 2003
    Inventors: Barbara A. Foster, Farzan Rastinejad
  • Publication number: 20020048271
    Abstract: The invention is in the field of cancer treatment. In particular, the present invention provides pharmaceutical compounds capable of interacting with mutant and non-mutant forms of cancer-related regulatory proteins such that the mutant protein regains the capacitv to properly interact with other macromolecules thereby restoring or stabilizing all or a portion of its wild type activity. Regulatory proteins include members of the p53 protein family such as. for example, p53, p63 and p73. The compounds of the invention are useful for cancer treatment. Methods for screening for such pharmacological compounds are also provided.
    Type: Application
    Filed: May 23, 2001
    Publication date: April 25, 2002
    Inventors: Farzan Rastinejad, Barbara A. Foster, Heather A. Coffey, Richard D. Connell
  • Patent number: 5172686
    Abstract: A device for supplying air or medical gases in a conditioned, particularly a moistened and/or heated state to a patient, through an air pipe. The device includes at least one component to be connected to said air pipe, the component being formed by a cylinder-shaped element with an inner tube through which the moistened air flows, which cylinder-shaped element is fitted with self-regulating heating resistors which heat the air flowing through the tube, while the cylinder-shaped tube from one element at least is filled with a material which adsorbs or absorbs the water supplied by a water-supply line from a container, and has a good air-permeability.
    Type: Grant
    Filed: September 19, 1989
    Date of Patent: December 22, 1992
    Inventor: Jean-Michel Anthony
  • Patent number: D776486
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: January 17, 2017
    Inventor: Barbara Foster